JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis

Arthritis and Rheumatism

Volumn 64, Issue 9, 2012, Pages 3006-3015

  Dees, Clara ^a   Tomcik, Michal ^a,c   Palumbo Zerr, Katrin ^a   Distler, Alfiya ^a   Beyer, Christian ^a   Lang, Veronika ^a   Horn, Angelika ^a   Zerr, Pawel ^a   Zwerina, Jochen ^a   Gelse, Kolja ^a   Distler, Oliver ^b   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; BLEOMYCIN; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANIMALS; ENZYME INHIBITORS; FEMALE; FIBROSIS; HUMANS; JANUS KINASE 2; MALE; MICE; MIDDLE AGED; PHOSPHORYLATION; PYRIMIDINES; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84865637745     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34500     Document Type: Article

References (33)

1. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
3. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
4. Yamaoka K, Saharinen P, Pesu M, Holt VE III, Silvennoinen O, O'Shea JJ,. The Janus kinases (Jaks). Genome Biol 2004; 5: 253.
5. Baker SJ, Rane SG, Reddy EP,. Hematopoietic cytokine receptor signaling. Oncogene 2007; 26: 6724-37.
6. Valentino L, Pierre J,. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006; 71: 713-21.
7. Verstovsek S,. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 2009; 2009: 636-42.
8. Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J, et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008; 58: 2553-64.
9. LeRoy EC, Medsger TA Jr,. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
10. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658-68.
11. Distler JH, Jungel A, Pileckyte M, Zwerina J, Michel BA, Gay RE, et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007; 56: 4203-15.
12. Dees C, Tomcik M, Zerr P, Akhmetshina A, Horn A, Palumbo K, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011; 70: 1304-10.
13. Palumbo K, Zerr P, Tomcik M, Vollath S, Dees C, Akhmetshina A, et al. The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011; 70: 1320-6.
14. Dees C, Zerr P, Tomcik M, Beyer C, Horn A, Akhmetshina A, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011; 63: 1396-404.
15. Woessner JF Jr,. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-7.
16. Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208: 961-72.
17. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22.
18. Marquart S, Zerr P, Akhmetshina A, Palumbo K, Reich N, Tomcik M, et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum 2010; 62: 3467-76.
19. Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, et al. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med 2011; 17: 845-53.
20. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
21. Lasho T, Tefferi A, Pardanani A,. Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia 2010; 24: 1378-80.
22. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009; 114: 5024-33.
23. Beyer C, Schett G, Distler O, Distler JH,. Animal models of systemic sclerosis: prospects and limitations [review]. Arthritis Rheum 2010; 62: 2831-44.
24. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M,. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 47-51.
25. Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 2010; 78: 257-68.
26. Shi Y, Zhang Y, Wang C, Du C, Zhao S, Qi Z, et al. Suppressor of cytokine signaling-1 reduces high glucose-induced TGF-β1 and fibronectin synthesis in human mesangial cells. FEBS Lett 2008; 582: 3484-8.
27. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-27.
28. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A,. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011; 25: 218-25.
29. Santos FP, Verstovsek S,. JAK2 inhibitors: what's the true therapeutic potential? Blood Rev 2011; 25: 53-63.
30. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62.
31. Charles C, Clements P, Furst DE,. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 1683-91.
32. Kim R, Meyer KC,. Therapies for interstitial lung disease: past, present and future. Ther Adv Respir Dis 2008; 2: 319-38.
33. Swigris JJ, Brown KK, Make BJ, Wamboldt FS,. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med 2008; 102: 1675-80.